anti-TRAIL-R3 (human) mAb (HS301)
| Code | Size | Price |
|---|
| AG-20B-0024-C100 | 100 ug | £300.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: IgG1
Antibody Clonality: Monoclonal
Antibody Clone: HS301
Regulatory Status: RUO
Target Species: Human
Applications:
- Flow Cytometry
- Immunocytochemistry (ICC)
Shipping:
-20°C
Storage:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
TRAIL Receptor 3; DcR1; TRID; TNFRSF10C; CD263
Concentration:
1mg/ml
EClass:
32160000
Form (Short):
liquid
Formulation:
Liquid. In PBS containing 10% glycerol and 0.02% sodium azide.
Handling Advice:
After opening, prepare aliquots and store at -20°C.Avoid freeze/thaw cycles.
Immunogen:
Recombinant human TRAIL-R3 (DcR1).
Long Description:
Monoclonal Antibody. Recognizes human TRAIL-R3. Does not cross-react with human TRAIL-R1, -R2 or -R4. Isotype: Mouse IgG1. Clone: HS301. Applications: FACS, ICC. Liquid. In PBS containing 10% glycerol and 0.02% sodium azide. TRAIL-R3 is a receptor for the cytotoxic ligand TRAIL. It lacks a cytoplasmic death domain and hence is not capable of inducing apoptosis. Protects cells against TRAIL mediated apoptosis by competing with TRAIL-R1 and R2 for binding to the ligand.
NCBI, Uniprot Number:
O14798
Package Type:
Plastic Vial
Product Description:
TRAIL-R3 is a receptor for the cytotoxic ligand TRAIL. It lacks a cytoplasmic death domain and hence is not capable of inducing apoptosis. Protects cells against TRAIL mediated apoptosis by competing with TRAIL-R1 and R2 for binding to the ligand.
Purity:
>95% (SDS-PAGE)
Source / Host:
Purified from concentrated hybridoma tissue culture supernatant.
Specificity:
Recognizes human TRAIL-R3. Does not cross-react with human TRAIL-R1, -R2 or -R4.
Transportation:
Non-hazardous
UNSPSC Category:
Primary Antibodies
UNSPSC Number:
12352203
Use & Stability:
Stable for at least 1 year after receipt when stored at -20°C.
References
TNF-Related Apoptosis-Inducing Ligand Mediates Tumoricidal Activity of Human Monocytes Stimulated by Newcastle Disease Virus: B. Washburn, et al.; J. Immunol. 170, 1814 (2003) | TRAIL regulates normal erythroid maturation through an ERK-dependent pathway: P. Secchiero, et al.; Blood 103, 517 (2004) | Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs: T.M. Ganten, et al.; Cell Death Differ. 11 Suppl 1, 86 (2004) | cFLIPL inhibits tumor necrosis factor-related apoptosis-inducing ligand-mediated NF-kappaB activation at the death-inducing signaling complex in human keratinocytes: T. Wachter, et al.; J. Biol. Chem. 279, 52824 (2004) | Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sezary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expression: E. Contassot, et al.; Blood 111, 4780 (2008) | The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2: T. Hartwig, et al.; Mol. Cell 65, 730 (2017)